collyre en solution en récipient unidose clinical trials
4 indexed studies · 0 currently recruiting
- Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
Safety and Efficacy of a Unilateral Subretinal Administration of HORA PDE6B in Patients with Retinitis Pigmentosa Harbouring Mutations in the PDE6B Gene Leading to a Defect in PDE6ß Expression
This study is testing a new gene therapy for people with retinitis pigmentosa caused by a specific faulty gene. It's looking at how safe the treatment is and if it helps improve vision. Researchers are giving the treatment into one eye.
For: retinitis pigmentosaFrance - AuthorisedTherapeutic exploratory (Phase II)
SYMBOL CLINICAL : Treatment of severe ocular chemical burns by subconjunctival injection of allogeneic mesenchymal stem cells: a multicentre, single-arm, open-label phase II trial
This study is looking at a new way to treat severe eye burns caused by chemicals. It uses special cells from donors, called mesenchymal stem cells, injected near the eye. Doctors want to see if this treatment can stop the eye from developing a hole in its surface.
For: Patient with severe eye chemical burnsFrance - AuthorisedTherapeutic exploratory (Phase II)
Antisense Oligonucleotide Eye Drops Against IRS-1 to Treat Pathological Corneal Neovascularisation in Aniridia-Associated Keratopathy (Olisens-Aniridia)
This study is testing new eye drops called OLISENS for people with a rare eye condition called aniridia, which can cause new blood vessels to grow on the clear front part of the eye (cornea). The drops aim to reduce these unusual blood vessels.
For: Corneal Neovascularization in Aniridia-associated KeratopathyGermany - AuthorisedTherapeutic exploratory (Phase II)
Antisense Oligonucleotide Eye Drops against IRS-1 to Optimize Pretransplant Lymphangio-regression Prior to High-Risk Keratoplasty (Olisens-Precon)
This study is testing new eye drops called OLISENS for adults with specific eye damage before a high-risk cornea transplant. The aim is to reduce abnormal blood vessels in the eye, which may improve transplant success. It's a phase II trial to check safety and how well it works.
For: Pathologically prevascularized corneas due to herpetic keratopathy prior to “high-risk” corneal transplantation (keratoplasty)Germany